低屈服点钢剪切耗能板抗震性能试验

鉴于目前对国产低屈服点钢材生产剪切板阻尼器的研究和应用还没有系统开展,采用宝山钢铁股份有限公司自主研发生产的低屈服点钢LYP160,设计制作了3种不同尺寸的剪切板阻尼器,开展其低周往复循环荷载试验,并在试验基础上,对影响剪切板耗能性能的因素进行了分析.研究结果表明:由国产LYP160制成的剪切耗能板在低周反复荷载作用下,滞洄曲线饱满,具有良好的耗能性能;经过合理设计和施工,该剪切板可以作为消能阻尼器应用于实际工程

Clinical study of NFLX (norfloxacin) in complicated urinary tract infections

1984年7月から同11月までの間に当大学および関連19施設で経験した難治性の複雑性尿路感染症64例を対象として, 新しく開発されたquinolone carboxylic acid系薬剤のNFLXを投与し, 臨床効果を検討した.なお起炎菌が証明されなかったり, 真菌の検出された20例は除外し, 計44例を検討対象とした.投与方法は1日600 mg(分3), 14日間とした.効果判定はUTI薬効評価基準に準じて行ない, MICも測定した.疾患別の有効率は単独感染62.1%, 混合感染60.0%で, 単独感染のカテーテル留置例の有効率は50%であった.従来の本剤による報告では有効率が52%～85%であり, 今回の成績が平均61%とやゝ低いが, G-1, G-5のカテーテル留置例が多かった結果と考えられる.従ってカテーテル留置群を除くと有効率は67%となり, 経口剤単独治療としては満足できるものといえた.細菌学的効果は分離株61株中65.6%に効果を認め, 既存の抗菌剤より優れていた.最も多く分離されたP. aeruginosaのMIC分布をみると, MIC 3.13以下に効果を認め, 評価できる結果であった.副作用は軽度の胃腸障害を4例に認め, GOTの上昇を1例に認めたに過ぎない.以上の成績より, NFLXは経口抗菌剤として複雑性尿路感染症に有効かつ安全性の高い有用な薬剤といえるThe new chemotherapeutic agent NFLX was orally administered 600 mg a day for 5 consecutive days in 44 cases having complicated urinary tract infection, and its clinical efficacy was evaluated. They consisted of 8 marked effective cases, 19 moderately effective cases and 17 ineffective cases, and its overall clinical efficacy was 61%. The bacteria disappeared in 10 cases, and decreased in 9 cases. Thirteen cases showed bacterial alternation, and 12 cases remained unchanged. By type of disease group, the efficacy was slightly inferior in the indwelling catheter group compared with that of the nonindwellt group

Amplitude analysis of the decays D0 → π+π−π+π− and D0 → π+π−π0π0*

Using e+e− annihilation data corresponding to an integrated luminosity of 2.93 fb−1 taken at the center-of-mass energy √s = 3.773 GeV with the BESIII detector, a joint amplitude analysis is performed on the decays D0 → π+π−π+π− and D0 → π+π−π0π0 (non-η). The fit fractions of individual components are obtained, and large interferences among the dominant components of the decays D0 → a1(1260)π, D0 → π(1300)π, D0 → ρ(770)ρ(770), and D0 → 2(ππ)S are observed in both channels. With the obtained amplitude model, the CP-even fractions of D0 → π+π−π+π− and D0 → π+π−π0π0 (non-η) are determined to be (75.2 ± 1.1stat. ± 1.5syst.) % and (68.9 ± 1.5stat. ± 2.4syst.)%, respectively. The branching fractions of D0 → π+π−π+π− and D0 → π+π−π0π0 (non-η) are measured to be (0.688 ± 0.010stat. ± 0.010syst.)% and (0.951 ± 0.025stat. ± 0.021syst.)%, respectively. The amplitude analysis provides an important model for the binning strategy in measuring the strong phase parameters of D0 → 4π when used to determine the CKM angle γ(φ3) via the B− → DK− decay

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements